prodiginine: prodigiosin-like pigments with antimicrobial & antimalarial activity; RN is from 9th CI; cpd not in Chemline 9/10/82 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 135829285 |
| SCHEMBL ID | 22003278 |
| MeSH ID | M0055699 |
| Synonym |
|---|
| 1h-pyrrole, 2-(3-methoxy-2-(1h-pyrrol-2-ylmethylene)-2h-pyrrol-5-yl)- |
| 24311-00-0 |
| prodiginine |
| SCHEMBL22003278 |
Prodiginines are a large family of tripyrrole alkaloids that contain natural members produced by various bacteria and non-natural members obtained from chemical synthesis, enzymatic synthesis, and mutasynthesis. Most of them are characterized by a common pyrrolylpyrromethene skeleton.
| Excerpt | Reference |
|---|---|
| "Prodiginines are a large family of microbial secondary metabolites with a core structure of tripyrrole rings. " | ( Structures, biosynthesis, and bioactivities of prodiginine natural products. Gao, Q; He, S; Li, P; Liu, L; Liu, Y; Zhang, X, 2022) |
| "Prodiginines are a family of red-pigmented secondary metabolites with multiple biological activities. " | ( Stringent Starvation Protein Regulates Prodiginine Biosynthesis via Affecting Siderophore Production in Ding, M; Meng, Q; Yin, J; Yu, Z; Zha, F; Zhang, J, 2021) |
| "Prodiginines are a large family of tripyrrole alkaloids that contain natural members produced by various bacteria and non-natural members obtained from chemical synthesis, enzymatic synthesis, and mutasynthesis. " | ( Insights into the anti-infective properties of prodiginines. Liu, X; Peng, Y; Wang, Y; Wu, W; You, Z; Zhang, J; Zhang, S, 2019) |
| "Prodiginines are a family of linear and cyclic oligopyrrole red-pigmented compounds possessing antibacterial, anticancer and immunosuppressive activities and are produced by actinomycetes and other eubacteria. " | ( QSAR and pharmacophore modeling of natural and synthetic antimalarial prodiginines. Bharate, SB; Singh, B; Vishwakarma, RA, 2013) |
| "Prodiginines are a family of natural red pigmented secondary metabolites, produced by different bacteria and most of them are characterized by a common pyrrolylpyrromethene skeleton." | ( New insights on the antitumoral properties of prodiginines. Pérez-Tomás, R; Viñas, M, 2010) |
| "Prodiginines are a class of red-pigmented natural products with immunosuppressant, anticancer, and antimalarial activities. " | ( Structure and function of the RedJ protein, a thioesterase from the prodiginine biosynthetic pathway in Streptomyces coelicolor. Alhamadsheh, M; Challis, GL; Florova, G; Reynolds, KA; Singh, R; Smith, JL; Sydor, PK; Whicher, JR, 2011) |
| "Prodiginines are a family of linear and cyclic oligopyrrole red-pigmented compounds. " | ( Antimalarial activity of natural and synthetic prodiginines. Alhamadsheh, M; Challis, GL; Haynes, SW; Kelly, JX; Papireddy, K; Reynolds, KA; Salem, SM; Smilkstein, M, 2011) |
| "Prodiginines are a large family of pigmented oligopyrrole antibiotics with medicinal potential as immunosuppressants and antitumour agents that are produced by several actinomycetes and other eubacteria. " | ( Analysis of the prodiginine biosynthesis gene cluster of Streptomyces coelicolor A3(2): new mechanisms for chain initiation and termination in modular multienzymes. Bibb, MJ; Cerdeño, AM; Challis, GL, 2001) |
| Excerpt | Reference |
|---|---|
| " Each analogue reduced parasitemia by more than 90% after 25 (mg/kg)/day dosing and in some cases provided a cure." | ( Antimalarial activity of natural and synthetic prodiginines. Alhamadsheh, M; Challis, GL; Haynes, SW; Kelly, JX; Papireddy, K; Reynolds, KA; Salem, SM; Smilkstein, M, 2011) |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (20.83) | 29.6817 |
| 2010's | 29 (60.42) | 24.3611 |
| 2020's | 9 (18.75) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 8 (16.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 42 (84.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||